NMRA · Neumora Therapeutics, Inc. · Documents
$0.37
-0.02 (-5.43%)
At close · Oct 30
Return incl. dividend (before tax)
Q4 2025 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the Company expects to be able to obtain additional funding, the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$69.00M
Shares
187.90M
Volume · Oct 30
1.11M
Avg daily vol (3M)
1.45M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
Key facts
CIK
1885522
CUSIP
640979100
13F (30d)
22 filings
22 filers
Visit website
Investor relations